In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals Inc (XERS), with a price target of $27. The company’s shares closed yesterday at $10.32, close to its 52-week low of $9.21.
Yang noted:
“We do not see earnings as the most important driver of value at this point. Xeris continues to invest with key hires across the company in preparation for a the Gvoke HypoPen launch in 4Q19. The PDUFA goal date for the Gvoke HypoPen is and we believe FDA approval is likely on time.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.4% and a 50.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals Inc with a $27 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.98 and a one-year low of $9.21. Currently, Xeris Pharmaceuticals Inc has an average volume of 192.8K.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company. It offers XeriSol™ and XeriJect™ formulation technologies. The firm focuses on the development of patient-friendly injectable drugs to address unmet medical needs. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
